Tech Company Financing Transactions
Arvinas Funding Round
Arvinas closed a $32.5 million financing round on 7/22/2019. Backers included private investors.
Transaction Overview
Company Name
Announced On
7/22/2019
Transaction Type
Venture Equity
Amount
$32,499,996
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 1 investor participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5 Science Park 395 Winchester Ave.
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Overview
Arvinas is a pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Houston
Chief Financial Officer
Sean Cassidy
Chief Scientific Officer
Ian Taylor
Chief Technical Officer
Andrew Crew
Vice President
Angela Cacace
Vice President
Kimberly Wehger
VP - Bus. Development
Matthew Batters
VP - Bus. Development
Randy Teel
VP - Human Resources
Steve Weiss
VP - Manufacturing
John Grosso
VP - Operations
Marcia Moore
Browse more venture capital transactions:
Prev: 7/22/2019: Qualio venture capital transaction
Next: 7/23/2019: UVeye venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs